---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-26-000056"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2026-08-11T11:32:26+00:00"
generated_at: "2026-08-11T11:35:21.376267+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neurogene Q2 net loss $34.5M; NGN-401 100% milestone gains; cash to 1Q29

## Summary
- Q2 2026 net loss $34.5M vs $22.0M YoY; R&D $25.5M, G&A $11.2M.
- Cash $225.4M at June 30; pro forma $360.2M after $134.8M net from July offering; runway into 1Q29.
- NGN-401 Phase 1/2: 100% (N=10) improved CGI-I and gained ≥1 milestone; avg 4.7 milestones, no plateau through 30 months.
- Embolden topline data expected 2H 2027; PPQ runs for BLA complete by end-2026; NGN-401 well-tolerated (N=35).
- Oversubscribed public offering raised ~$144M gross proceeds, including full underwriter option exercise.

## SEC filing metadata
- accession: 0001404644-26-000056
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2026-08-11T11:32:26+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/0001404644-26-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/ngne-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-26-000056
- JSON: https://secwatch.observer/filing/0001404644-26-000056.json
- Plain text: https://secwatch.observer/filing/0001404644-26-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.